University of Arizona Cancer Center | Strategic Alliance Partners

The gift is from the estate of Tom and Catherine Culley, longtime residents of the East Coast and worldwide travelers.

Data collected with patient-reported outcomes show that pembrolizumab, with or without bevacizumab, is associated with a favorable toxicity profile in effectively treating women with persistent, recurrent, or metastatic cervical cancer.

Ultimately, the goal is for every eligible patient to receive PARP inhibition in the frontline maintenance setting alone or in combination with bevacizumab, one expert says.